High disease activity in ankylosing spondylitis is associated with increased serum sclerostin level and decreased wingless protein-3a signaling but is not linked with greater structural damage

BMC Musculoskeletal Disorders

Volumn 14, Issue , 2013, Pages

  Korkosz, Mariusz ^a   Ga̧sowski, Jerzy ^a   Leszczyński, Piotr ^b   Pawlak Buś, Katarzyna ^b   Jeka, Sławomir ^c   Kucharska, Ewa ^d   Grodzicki, Tomasz ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^c Department of Rheumatology and Connective Tissue Diseases   (Poland)

^d Vadimed Clinic   (Poland)

Author keywords

Ankylosing spondylitis; BASDAI; New bone formation; Sclerostin; Wnt

Indexed keywords

ALKALINE PHOSPHATASE; DICKKOPF 1 PROTEIN; OSTEOGENIC PROTEIN 1; OSTEOPROTEGERIN; SCLEROSTIN; STROMELYSIN; WNT PROTEIN;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BLOOD LEVEL; CERVICAL SPINE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE MARKER; FEMALE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; SPINE RADIOGRAPHY;

ADULT; BIOLOGICAL MARKERS; BONE MORPHOGENETIC PROTEINS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GENETIC MARKERS; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; SPONDYLITIS, ANKYLOSING; WNT3A PROTEIN;

EID: 84875031391     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-14-99     Document Type: Article

References (17)

1. Ankylosing spondylitis. Braun J, Sieper J, Lancet 2007 369 9570 1379 1390 10.1016/S0140-6736(07)60635-7 17448825
2. Progress in spondylarthritis. Mechanisms of new bone formation in spondyloarthritis. Lories RJ, Luyten FP, de Vlam K, Arthritis Res Ther 2009 11 2 221 10.1186/ar2642 19439035
3. Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression. Heiland GR, Zwerina K, Baum W, Kireva T, Distler JH, Grisanti M, Asuncion F, Li X, Ominsky M, Richards W, Schett G, Zwerina J, Ann Rheum Dis 2010 69 12 2152 2159 10.1136/ard.2010.132852 20858621
4. BMP and BMP inhibitors in bone. Rosen V, Ann N Y Acad Sci 2006 1068 19 25 10.1196/annals.1346.005 16831902
5. Bone morphogenic proteins in destructive and remodelling arthritis. Lories R, Luyten F, Arthritis Res Ther 2007 9 207 214 10.1186/ar2135 17381828
6. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Glass DA III, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, Taketo MM, Long F, McMahon AP, Lang RA, Karsenty G, Dev Cell 2005 8 5 751 764 10.1016/j.devcel.2005.02.017 15866165
7. Osteoclast differentiation and activation. Boyle WJ, Simonet WS, Lacey DL, Nature 2003 423 6937 337 342 10.1038/nature01658 12748652
8. Matrix metalloproteinases in arthritic disease. Murphy G, Knauper V, Atkinson S, Butler G, English W, Hutton M, Stracke J, Clark I, Arthritis Res 2002 4 Suppl 3 39 S49 10.1186/ar572 12110122
9. Quantification of biochemical markers of bone turnover by kinetic measures of bone formation and resorption in young healthy females. Weaver CM, Peacock M, Martin BR, McCabe GP, Zhao J, Smith DL, Wastney ME, J Bone Miner Res 1997 12 10 1714 1720 10.1359/jbmr.1997.12.10.1714 9333133
10. Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment. Appel H, Janssen L, Listing J, Heydrich R, Rudwaleit M, Sieper J, Arthritis Res Ther 2008 10 5 125 10.1186/ar2537 18945353
11. High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis. Heiland GR, Appel H, Poddubnyy D, Zwerina J, Hueber A, Haibel H, Baraliakos X, Listing J, Rudwaleit M, Schett G, Sieper J, Ann Rheum Dis 2012 71 4 572 574 10.1136/annrheumdis-2011-200216 22186710
12. Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis. Taylan A, Sari I, Akinci B, Bilge S, Kozaci D, Akar S, Colak A, Yalcin H, Gunay N, Akkoc N, BMC Musculoskelet Disord 2012 13 1 191 10.1186/1471-2474-13-191 23025387
13. Ankylosing spondylitis disease activity score (ASDAS): defining cut-off values for disease activity states and improvement scores. Machado PF, Landewe RF, Lie E, Kvien TK, Tore K, FAU KT, Braun JF, Baker D, van der Heijde D, Ann Rheum Dis 2011 70 1 47 53 10.1136/ard.2010.138594 21068095
14. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Appel H, Ruiz-Heiland G, Listing J, Zwerina J, Herrmann M, Mueller R, Haibel H, Baraliakos X, Hempfing A, Rudwaleit M, Sieper J, Schett G, Arthritis Rheum 2009 60 11 3257 3262 10.1002/art.24888 19877044
15. Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis. Daoussis D, Liossis SN, Solomou EE, Tsanaktsi A, Bounia K, Karampetsou M, Yiannopoulos G, Andonopoulos AP, Arthritis Rheum 2010 62 1 150 158 10.1002/art.27231 20039407
16. Roles of Wnt signalling in bone growth, remodelling, skeletal disorders and fracture repair. Macsai CE, Foster BK, Xian CJ, J Cell Physiol 2008 215 3 578 587 10.1002/jcp.21342 18247365
17. WNT-3A modulates articular chondrocyte phenotype by activating both canonical and noncanonical pathways. Nalesso G, Sherwood J, Bertrand J, Pap T, Ramachandran M, De Bari C, Pitzalis C, Dell'accio F, J Cell Biol 2011 193 3 551 564 10.1083/jcb.201011051 21536751